AOD-9604 reconstitution calculator

Real safety trials, a failed efficacy trial, and a route mismatch worth knowing

AOD-9604 is a synthetic fragment of the C-terminal end of human growth hormone, designed to isolate hGH's fat-reducing activity from its growth-promoting one. Unlike most compounds on this calculator hub, it has real human safety data: a pooled summary of six randomized, double-blind, placebo-controlled trials found it "indistinguishable from placebo" on safety — no anti-drug antibodies, no IGF-1 elevation, no negative effect on glucose tolerance, no serious adverse events.

Its efficacy record is a different story. The developer's pivotal Phase IIb obesity trial failed — its own 2007 announcement states "trial results do not support commercial viability of obesity project: programme is terminated," a disclosure made via a stock-exchange filing rather than a peer-reviewed publication. And that trial dosed AOD-9604 as an oral tablet, once daily for 12 weeks — not the injectable vial form this calculator, and most of today's compounding/research-chemical market, actually serves. Whatever the injectable form does in a person has not itself been tested against placebo in any study located for this site's evidence review.

Its regulatory status: AOD-9604 does not appear on FDA's current 503A Bulks List (updated May 14, 2026) in any category. It was previously nominated and flagged by FDA for immunogenicity concerns and for "serious adverse events... though causality is not clear," but that nomination was later withdrawn — both facts are real and reported together, not selectively. No FDA-approved product exists; DailyMed returns zero results.

What the tool below actually does is narrower than that context might suggest: it takes the vial size, diluent volume, and dose you type in and returns the concentration and draw volume that arithmetic implies — nothing more. It cannot confirm that a particular vial matches its label, that the injectable route carries the same trial evidence as the oral tablet that was tested, or that a compounding pharmacy is currently permitted to sell it. A correct-looking syringe reading is not evidence that any of those things are true.

Sources: Stier H, Vos E, Kenley D, J Endocrinol Metab 2013 (six-trial pooled safety summary), Dominikowski A et al., Frontiers in Endocrinology 2026 (PMID 42395176), DailyMed structured-product-label search for "AOD9604" (zero results), and FDA's current 503A Bulks List plus its companion significant-safety-risk page, all independently checked August 2026. View the DailyMed search.